| Literature DB >> 17703895 |
Hans Theodor Eich1, Axel Gossmann, Andreas Engert, Jan Kriz, Henning Bredenfeld, Katja Hansemann, Roman Skripnitchenko, Corinne Brillant, Beate Pfistner, Susanne Staar, Volker Diehl, Rolf-Peter Müller.
Abstract
PURPOSE: The role of radiotherapy (RT) after intensive chemotherapy in patients with advanced stage Hodgkin's lymphoma (HL) is still unclear. The German Hodgkin Study Group (GHSG) randomized HD12 trial was designed to test whether consolidative RT in the region of initial bulky disease and of residual disease is necessary after effective chemotherapy. A quality control program based on a multidisciplinary panel of radiation oncologists, radiologists, and medical oncologists who reviewed all patients' staging and restaging imaging was initiated. METHODS AND MATERIALS: A total of 1661 patients aged 16 to 65 years with HL in Stage IIB (large mediastinal mass and/or E-lesions) or Stage III to IV were randomized from January 1999 to January 2003 according to a factorial design between: 8 esc.BEACOPP + RT (arm A), 8 esc.BEACOPP non-RT (arm B), 4+4BEACOPP + RT (arm C), 4+4BEACOPP non-RT (arm D).Entities:
Mesh:
Substances:
Year: 2007 PMID: 17703895 DOI: 10.1016/j.ijrobp.2007.04.035
Source DB: PubMed Journal: Int J Radiat Oncol Biol Phys ISSN: 0360-3016 Impact factor: 7.038